SS-31 Dosage Chart: 500mcg/Day, 5-On/2-Off (2026)

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Community doses are dramatically different from clinical trial doses — for good reason.

TAZPOWER Trial (Barth Syndrome): 40 mg SC daily for 12 weeks in patients with genetic cardiolipin deficiency causing heart failure (Thompson et al., 2021).

PROGRESS-HF Trial: 4 mg SC daily for 4 weeks in heart failure patients with reduced ejection fraction.

Phase I Safety: IV doses up to 250 mcg/kg (~17.5 mg for a 70 kg adult) showed no dose-limiting toxicity (Szeto, 2014).

Why community doses are much lower: Clinical trials targeted severe genetic/cardiac conditions requiring aggressive intervention. Community protocols use 500 mcg for general longevity/mitochondrial support. SS-31 binds cardiolipin with high affinity — there's a finite amount to stabilize. Lower daily dose with cycling provides sustained benefits with wide safety margin.

Preclinical speed: SS-31 improves mitochondrial ADP sensitivity within 1 hour in aged human muscle (Siegel et al., 2023) — one of the fastest-acting peptides documented.

Stacking Protocols

Community-documented stacking protocols (self-reported sources):

SS-31 + MOTS-c

Dual mitochondrial — structure + signaling

SS-31 500 mcg + MOTS-c 1 mg, both 5on/2off

SS-31 + NAD+

Mitochondrial optimization + fuel

SS-31 500 mcg 5on/2off + NAD+ 100 mg 2-3x/week

SS-31 + Epitalon

Mitochondria + telomere maintenance

Two key aging pathways covered

SS-31 stabilizes mitochondrial structure; MOTS-c activates metabolic signaling. Different mechanisms, complementary effects. For the full comparison, see our SS-31 vs MOTS-c.

Side Effects & Safety

Excellent safety profile — 40 mg daily was well-tolerated for 12+ weeks in TAZPOWER

No dose-limiting toxicity up to 0.25 mg/kg IV in Phase I

Occasional mild injection site irritation at community doses

Rare initial energy fluctuations — first few days only

No significant adverse events in any clinical trial

Community sources describe 500 mcg daily as generally well-tolerated, consistent with the absence of adverse events reported in clinical trials at significantly higher doses

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once SS-31 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

250 mcg

0.05 mL

5 units

500 mcg

0.1 mL

10 units

750 mcg

0.15 mL

15 units

1000 mcg

0.2 mL

20 units

Reconstitution B: 10 mg vial + 3 mL BAC water (3.33 mg/mL) — more BAC water for larger, easier-to-measure draws.

0.075 mL

7.5 units

0.225 mL

22.5 units

0.3 mL

30 units

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.